Drugs / ME-344
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02806817 | Jul 2016 → Oct 2018 | Her2-receptor negative breast cancer | Spanish National Cancer Research Centre | Completed | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT05824559 | Aug 2023 → Jul 2024 | colorectal cancer | MEI Pharma, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT01544322 | May 2012 → Aug 2014 | cancer | MEI Pharma, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02100007 | Apr 2014 → Jan 2016 | cancer | MEI Pharma, Inc. | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ME-344 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05824559 ↗ |
| Action | Inhibit | “This study evaluated the mitochondrial inhibitor ME-344 in combination with bevacizumab in patients with refractory metastatic colorectal cancer (mCRC).” PMID 39725778 ↗ Dec 2024 |
| Modality | Small molecule | “synthetic small molecule” NCT02806817 ↗ |
| Route | Intravenous | “Cycle 1 is 3 weekly IV infusions on Days 1, 8, and 15.” NCT01544322 ↗ |